Deposits from the Gadolinium contrast dyes used to perform many MRIs may remain in the body for weeks, months or even years. A growing number of lawsuits allege that these deposits may lead to symptoms associated with gadolinium toxicity or Gadolinium Deposition Disease.
The nationwide law firm of Bernstein Liebhard LLP is offering free, no-obligation legal reviews to individual who may be suffering from gadolinium MRI side effects. To obtain your case review, please call (888) 994-5118.
Gadolinium contrast dyes are used to enhance images on MRI screens.
Gadolinium MRI agents currently approved for use in the United States include:
The U.S. Food & Drug Administration (FDA) began investigating these agents in 2015, after two studies suggested that gadolinium deposits could remain in the brain for weeks or months following an MRI procedure.
In December 2017, the agency issued a class warning for gadolinium contrast dyes because of the risk of gadolinium retention.
While the FDA maintained that the only known gadolinium MRI side effect is a rare condition called nephrogenic systemic fibrosis (NSF) that occurs in a small subgroup of patients with pre-existing kidney failure, it acknowledged receiving reports of adverse events involving multiple organ systems in patients with normal kidney function. It’s not yet clear, however, if these events are related to gadolinium retention.
To mitigate the potential for gadolinium MRI side effects, the FDA ordered the drug’s manufacturers to update their labels with information about gadolinium retention and to conduct studies to better assess this risk. Patients will also be informed about the possibility of gadolinium retention prior to an MRI.
The FDA’s safety communication indicated that certain gadolinium MRI contrast dyes – known as linear agents – result in more retention and retention for a longer time compared to gadolinium products called macrocyclic agents.
Linear gadolinium contrast agents include:
“Gadolinium levels remaining in the body are higher after administration of Omniscan (gadodiamide) or OptiMARK (gadoversetamide) than after Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), or MultiHance (gadobenate dimeglumine),” the FDA stated. “Gadolinium levels in the body are lowest after administration of Dotarem (gadoterate meglumine), Gadavist (gadobutrol), and ProHance (gadoteridol); the gadolinium levels are also similar across these agents.”
Signs and symptoms of gadolinium toxicity or Gadolinium Deposition Disease include:
Some sufferers of gadolinium toxicity have also reported other symptoms, including gastrointestinal issues, such as diarrhea and abdominal pain, and cardiac issues such as abnormal heart rhythms.
Some have also described a persistent metallic taste or olfactory sensation. While a metallic taste often follows the immediate administration of gadolinium agents, it generally clears after a minute or so.
If you or a loved one underwent a gadolinium-based MRI and think you could be experiencing gadolinium MRI side effects as described above, you may be eligible to pursue compensation for medical billing and other injury related damages.
To learn more about filing a gadolinium MRI contrast agent lawsuit, call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.